Abstract
The hepatitis C Virus (HCV) is now known to be the chief cause of transfusion-associated non-A non-B hepatitis (NANBH). The prevalence of HCV infection was as-sessed by means of Abbott enzyme-linked immunosorbent assay for serum anti-HCV antibodies. 2222 serum samples were selected from different patient groups, accor¬ding to their risk of blood-borne viral infections. Anti-HCV antibodies were detected in 25 of 83 (30.12%) risk group (Haemodialysis patients and polytransfused patients with haemophilia, thalassemia, patients of cardiac surgery). Among healtyh subjects, wit¬hout risk factors for hepatitis, the overall prevalance of Anti-HCV was (0.14%).
Hepatit C virusu (HCV), transfüzyon ile ilişkili non-A, non-B hepatiti (NANBH)'nin başlıca nedenidir. HCV infeksiyon prevalansı Abbott'un anti-HCV antikorları için enzy-me-linked immunosorbent assay (ELISA) test kiti kullanılarak saptanmıştır. 2222 serum örneği, kan yoluyla viral infeksiyon bulaşma riski olan değişik hasta gruplarından toplanmıştır. Anti-HCV antikorları 83 risk grubunun (hemodiyaliz hastası, he¬mofili, thalassemi gibi politransfüze hastalar ve kalp cerrahisi hastaları) 25 (%30.12)'inde saptanmıştır. Hepatit risk faktörü bulunmayan sağlıklı bireylerde anti-HCV prevalansı ise %0.14 olarak saptanmıştır.
Keywords
Details
| Primary Language | English |
|---|---|
| Journal Section | Basic Medical Sciences |
| Authors | |
| Publication Date | December 22, 2009 |
| Submission Date | November 24, 2009 |
| Published in Issue | Year 1992 Volume: 9 Issue: 3-4 |
Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.